Myocardial remodeling and immunologic activation in patients with heart failure;Remodelado miocárdico y activación inmunitaria en pacientes con insuficiencia cardiaca

Revista Espanola de Cardiologia

Volumn 59, Issue 9, 2006, Pages 911-918

  Rivera Otero, Miguel ^a,g   Taléns Visconti, Raquel ^a   Jordán, Alejandro ^b   Sirera, Rafael ^a   Sevilla, Begoña ^c   Climent, Vicente ^d   Roselló, Esther ^a   Payá, Rafael ^e   Cortés, Raquel ^a   Sancho Tello, María J ^a   Valero, Ricardo ^f   González Molina, Andrés ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^g UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

Collagen; Cytokines; Heart failure; Ventricular remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 10; INTERLEUKIN 6; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGE; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION FUNCTION; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PREDICTION; PROTEIN BLOOD LEVEL; SEX; STATISTICAL SIGNIFICANCE;

EID: 33750970010     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13092799     Document Type: Article

References (31)

1. Takano H, Hasegawa H, Nagai T. Komuro I. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies. Intern Med. 2003;42:465-9.
2. Cleutjens JP, Creemers EE. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction. J Card Fail. 2002;8 Suppl 6:344-8.
3. Pauschinger M, Chandrasekharan K, Li J, Schwimmbeck PL, Noutsias M, Schultheiss HP. Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy. Herz. 2002;27:677-82.
4. Heeneman S, Cleutjens JP, Faber BC, Creemers EE, Van Suylen RJ, Lutgens E, et al. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis J Pathol. 2003;200:516-25.
5. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A. 2000;97:12746-51.
6. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension. 2001;38:1227-32.
7. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation. 2000;101:1527-32.
8. Sirera R, Salvador A, Roldán I, Talens R, González-Molina A, Rivera M. Quantification of proinflammatory cytokines in the urine of congestive heart failure patients. Its relationship with plasma levels. Eur J Heart Fail. 2003;5:27-31.
9. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-93.
10. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995; 92:1479-86.
11. Petretta M, Condorelli GL, Spinelli L, Scopacasa F, De Caterina M, Leosco D, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J. 2000;140:E28.
12. Yamaoka M, Yamaguchi S, Okuyama M, Tomoike H. Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha. Jpn Circ J. 1999;63:951-6.
13. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond). 2003;105:45-50.
14. Ferrari R. Interleukin-6: a neurohumoral predictor of prognosis in patients with heart failure: light and shadow. Eur Heart J. 2002;23:9-10.
15. Remme WJ, Swedberg K. European Society of Cardiology. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail. 2002;4:11-22.
16. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93:841-2.
17. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/ AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001; 104:2996-3007.
18. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490-8.
19. Remme WJ. Towards the better treatment of heart failure. Eur Heart J. 1998;19 Suppl L:36-42.
20. Schiller NE. Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of the American Society of Echocardiography. Circulation. 1991;84 Suppl 3:280-7.
21. Paul S. Ventricular remodeling. Crit Care Nurs Clin North Am. 2003;15:407-11.
22. Salton CJ, Chuang ML, O'Donnell CJ, Kupka MJ, Larson MG, Kissinger KV, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol. 2002;39:1055-60.
23. Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H, et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J. 2003;24:2180-5.
24. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108:1395-403.
25. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-98.
26. Anker SD, Von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464-70.
27. Abbate A, Bonanno E, Mauriello A, Bussani R, Biondi-Zoccai GG, Liuzzo G, et al. Widespread myocardial inflammation and infarct-related artery patency. Circulation. 2004;110:46-50.
28. Dembic Z, Loetscher H, Gubler U, Pan YC, Lahm HW, Gentz R, et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine. 1990;2:231-7.
29. Puhakka M, Magga J, Hietakorpi S, Penttila I, Uusimaa P, Risteli J, et al. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. J Card Fail. 2003;9:325-32.
30. Gurlek A, Kilickap M, Dincer I, Dandachi R, Tutkak H, Oral D. Effect of losartan on circulating TNFalpha levels and left ventricular systolic performance in patients with heart failure. J Cardiovasc Risk. 2001;8:279-82.
31. Eicken A, Fratz S, Gutfried C, Balling G, Schwaiger M, Lange R, et al. Hearts late after fontan operation have normal mass, normal volume, and reduced systolic function: a magnetic resonance imaging study. J Am Coll Cardiol. 2003;42:1061-5.